Advertisement

Topics

Companies Related to "BRIEF company targets immunotherapies genetically defined type diabetes" [Most Relevant Company Matches] RSS

16:24 EST 11th December 2018 | BioPortfolio

Here are the most relevant search results for "BRIEF company targets immunotherapies genetically defined type diabetes" found in our extensive corporate database of over 50,000 company records.

Showing "BRIEF company targets immunotherapies genetically defined type diabetes" Companies 1–25 of 5,700+

Relevant

Metabolex Incorporated

Metabolex discovers and develops new drugs for type 2 diabetes, bringing to the market novel drugs that address the molecular mechanisms underlying the disease. Such therapeutics are needed to more effectively control patients' blood glucose levels and impede progression of diabetes and its complications.Metabolex has a team of dedicated experts and a robust technology base in diabetes biology and...


Team Type 1 Foundation

Established in 2013, the Team Type 1 Foundation is a nonprofit organization pursuing a mission of education, empowerment and equal access to medicine for everyone affected by diabetes. Collaborating with governments, healthcare professionals, diabetes experts and individuals living with diabetes around the world, the Team Type 1 Foundation is bridging the ...

Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.


Bristol-Myers Squibb Company

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

Bristol-Myers Squibb Company & AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Bristol-Myers Squibb Company and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

The T1D Exchange

The T1D Exchange is a unique platform for collaborative data collection and sharing that consists of three overlapping components: a clinic-based registry with clinical, biological and other real-life information from individuals with type 1 diabetes, a registry that is coordinated through a network of clinical centers and an interactive online community f...

Glucose Health, Inc.

Glucose Health, Inc. dietary products engage the large and growing market of consumers aware of the seriousness of Type 2 diabetes and proactively seeking natural blood sugar health solutions. The CDC currently estimates 2 in 5 adults – 86 million Americans – will develop Type 2 diabetes in their lifetime. Glucose Health, Inc. dietary products ar...

Zucara Therapeutics

Zucara Therapeutics, a spin-off company by The Centre for Drug Research and Development (CDRD) and MaRS Innovation (MI), is developing the first drug therapy to prevent hypoglycemia in people with diabetes. The Company’s first-in-class therapeutic is aimed at inhibiting a hormone in the pancreas called somatostatin, which does not function properly in ...

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...

Team Type 1

Based in Atlanta, GA, Team Type 1 began as a grassroots initiative to motivate people to take control of their diabetes using cycling as a platform. It grew to become a world-class athletic program for all athletes with diabetes, including a professional men's cycling team, poised to compete at the 2012 Tour de France. Today, it is a global sports organiza...

Diamyd Medical AB (publ)

The purpose of the GAD65-based diabetes therapy Diamyd(R) is to prevent, delay, or stop the autoimmune attack on beta cells in type 1 diabetes and other forms of autoimmune diabetes, thereby preserving the body's capacity to regulate blood sugar. This reduces the risk for both acute and long term diabetes complications significantly.

Bristol-Myers Squibb and AstraZeneca

Bristol-Myers Squibb and AstraZeneca entered into a collaboration in January 2007 to enable the companies to research, develop and commercialize select investigational drugs for type 2 diabetes. The Bristol-Myers Squibb/AstraZeneca Diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treat...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

Point Therapeutics

Point Therapeutics, Inc is a Boston-based biopharmaceutical company dedicated to developing a family of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. DPPs are enzymes that appear to regulate several different physiological processes including those involved in tumor growth and host responses to cancer, type 2 diabetes, and immune responses to v...

DiObex

DiObex, Inc., a clinical-stage company based in San Francisco, is developing unique, first-in-class therapies for the critically under-served metabolic disease market. Our pipeline products address the markets for the treatment of type 1 diabetes, type 2 diabetes and its co-morbidities such as hypertension, dyslipidemia and visceral adiposity (often referred to collectively as “metabolic syndrom...

Exsulin Corporation

Based in Minneapolis, Exsulin Corporation has global rights to and pioneered the development of an experimental approach for the treatment of Type 1 and Type 2 diabetes with the goal of affecting the future of diabetes care and providing significant cost savings within the healthcare system. Exsulin has worked with leading research labs in multiple countries to develop the technology that has led ...

Creative Peptides develops pharmaceutical products

Creative Peptides develops pharmaceutical products based on C-peptide Our research will significantly improve on the treatment of long-term complications of type 1 diabetes. Complications of type 1 diabetes are currently not effectively and safely treatable and cause great suffering in afflicted patients as well as vast costs to society

DiabetesMine.com

DiabetesMine.com is an information resource and a community networking place for people affected by diabetes. Its creator, Amy Tenderich, is a journalist who lives with Type 1 diabetes herself, and shares an unusual “cynically optimistic” view of the trials of living with this condition. She speaks creatively and from the heart — to people with dia...

DreaMed Diabetes

DreaMed Diabetes was established in 2014 to develop and commercialize diabetes treatment and management solutions. Its flagship product, GlucoSitter™, is a closed-loop insulin delivery system for patients with type 1 and type 2 diabetes. Additional development programs include insulin-treatment-profiling systems for diabetic clinics, patient decision-...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by ident...

Inspired by Diabetes

Inspired by Diabetes is a global campaign asking people moved by the triumphs and challenges of those with diabetes and those who care for them to express their inspiration and share it with others around the world. The program is a collaboration between global champions Eli Lilly and Company, the International Diabetes Federation's (IDF) Unite for Diabetes initiative and the International Society...

GI Dynamics, Inc.

GI Dynamics is focused on the development and commercialization of effective, non-surgical treatments for type 2 diabetes and obesity. The company’s patented EndoBarrier® technology has the potential to deliver effective treatments for people combating weight problems and diabetes or diabetes risk factors.

Diabetes & Glandular Disease Clinic of San Antonio

The Diabetes & Glandular Disease Clinic, P.A. (DGD) offers the best in treatment for hormonal and metabolic disorders such as type 1 and 2 diabetes, gestational diabetes, thyroid disease, osteoporosis, lipid disorders (high cholesterol), pituitary/adrenal gland problems, menstrual disorders and hirsutism (excessive facial hair on women). All our doctors are board-certified in Endocrinology & Metab...


More From BioPortfolio on "BRIEF company targets immunotherapies genetically defined type diabetes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks